Scientist – Off-Target Genomics (Gene Therapy)

Eurofins•Boston, MA

8h•$104,000 - $112,320•Onsite

About The Position

We are seeking a Scientist – Off-Target Genomics (Gene Therapy) to lead and execute genomic safety assessment strategies for gene editing therapeutics. This role focuses on evaluating off-target effects, genomic integrity, and emerging genome editing modalities.

Requirements

B.S. with 5+ years, M.S. with 3–7 years, or Ph.D. with 2–4 years of industry experience in genomics, molecular biology, biochemistry, or a related field
Hands-on experience in off-target assessment and/or genomic safety evaluation for gene editing therapeutics
Strong working knowledge of CRISPR-based genome editing technologies
Experience with next-generation sequencing workflows and data interpretation
Familiarity with base editing, prime editing, and associated genotoxicity considerations
Demonstrated scientific problem-solving skills; assay development experience is a plus
Strong communication skills with the ability to present complex data to diverse audiences
Self-motivated, adaptable, and able to work both independently and collaboratively

Nice To Haves

Experience with optical genome mapping (e.g., Bionano platform)
Understanding of regulatory expectations for genomic safety (IND/BLA submissions)
Exposure to human diversity-informed off-target methods (e.g., ONE-seq)
Authorization to work in the U.S. without sponsorship

Responsibilities

Lead genomic safety assessment packages, including off-target discovery, verification, validation, and genomic integrity characterization
Apply and evaluate off-target discovery approaches using: In silico tools (e.g., CALITAS, CRISPRme, Cas-OFFinder), Biochemical methods (e.g., SITE-seq, CIRCLE-seq, CHANGE-seq, Digenome-seq), Cell-based assays (e.g., GUIDE-seq, INDUCE-seq)
Drive off-target confirmation using sequencing-based approaches such as AmpSeq, rhAmpSeq, and hybrid capture
Assess genomic integrity using orthogonal platforms including karyotyping, optical genome mapping, and whole genome sequencing (WGS)
Evaluate genotoxicity risks associated with next-generation genome editing technologies, including base and prime editing
Support and/or lead development of novel assays for emerging genome editing modalities (Gen 5+)
Integrate biodistribution data to inform tissue selection for off-target verification studies
Collaborate cross-functionally and present findings clearly to scientific and project teams